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Abstract
We have characterized mouse AE1-mediated 36Cly influx and surface AE1 polypeptide expression in Xenopus oocytes
injected with cRNA encoding two classes of loss-of-function mutants. The first arose spontaneously. Chimeric mutants
constructed with a functional AE1 cDNA localized the site of spontaneous mutation to the transmembrane domain, and
DNA sequencing revealed two missense mutations encoding the double-mutant polypeptide V728FrM730I. Each mutation
individually produced only partial loss of AE1 transport activity, and coexpression of the individual mutants did not restore
full activity. The functional changes produced by the mutations correlated with reduced fractional accumulation of
polypeptides at the oocyte surface. The V728FrM730I polypeptide expressed in mammalian cells displayed complete
endoH resistance and rapid degradation. We also examined the effect on AE1 function of engineered removal of its
hydrophilic carboxy-terminus. Both D 890 and the internal deletion D 890–917 were functionally inactive in Xenopusc c
oocytes. Lack of transport activity correlated with lack of detectable polypeptide accumulation at the oocyte surface.
Coexpression with wt AE1 of some, but not all, of these AE1 mutants partially suppressed wt AE1-mediated 36Cly uptake.
In contrast, coexpression with wt AE1 of soluble N-terminal AE1 fragments was not inhibitory. q 1997 Elsevier Science
B.V.
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1. Introduction
The band 3-related AE anion exchanger gene fam-
w xily includes at least three 1 and possibly four genes
w x2 which encode at least 14 mRNA transcripts, pre-
dicted in turn to encode at least nine polypeptide
w xproducts 3–5 . Seven of these AE polypeptides are
complex polytopic transmembrane proteins which
mediate ClyrHCOy exchange and can serve as an-3
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ion exchangers of broader substrate specificity. The
molecular mechanism of this anion exchange remains
unknown despite the accrual over many years of
much biochemical, kinetic, and molecular biological
information. Our understanding of this mechanism
will be greatly enhanced by knowledge of the struc-
ture of the transmembrane domains of AE proteins.
Structural analysis of the red cell AE1 anion ex-
changer by electron microscopic tomography of re-
constituted two-dimensional ordered arrays of the
purified protein is proceeding through increasing lev-
w xels of resolution 6 . In addition, NMR structures of
individual transmembrane helices in organic solvents
w xare being solved 7 . However, assessment of the
functional consequences of mutations in AE poly-
peptides remains an important component of the ex-
perimental repertoire, allowing insight into the rela-
tion between protein structure and transport.
The mutations analyzed to date have been both
naturally occurring and genetically engineered. Muta-
tions in human AE1 proteins have been documented
in individuals with heritable red cell shape abnormali-
w xties 8–12 . Sometimes, the mutant protein is present
w xin the red cell membrane 8,12 , but more often the
mutations accompanied by hemolytic anemias are
characterized by red cells lacking mutant polypeptide
w xand with diminished total AE1 protein content 9–11 .
Most of these individuals appear to be obligate
heterozygotes. This reduction in AE1 content of the
circulating red cell by G40% predisposes to hemoly-
sis secondary to the deficit of membrane attachment
w xsites for the cytoskeleton 11 , and perhaps also to
w xpartial destabilization of the lipid bilayer 17 .
Another source of molecular variants in human
AE1 has been the evaluation of red cells bearing
serologically defined, low frequency blood group
w xantigens 13–15 . Most recently, two viable AE1 null
mutations have been described, one discovered in a
w xcohort of Japanese cattle 16 and the other engi-
w xneered into AE1 knockout mice 17 .
Most of the AE1 mutations which result in no
accumulation of mutant polypeptide are thought to
result from aberrant folding during biosynthesis, or
from aberrant post-translational processing. Some of
the aberrant folding pathways followed by mutant
polypeptides display temperature sensitivity, such that
lower temperatures are permissive for expression of
wild-type phenotype. Examples of the application of
this concept to recombinant expression of polytopic
membrane transport proteins include surface expres-
sion of wt nicotinic acetylcholine receptor in fibrob-
w xlasts at 288C, but not at 378C, 18 and surface
expression in Xenopus oocytes of the prevalent
DF508 mutant of the cystic fibrosis transmembrane
w xregulator protein 19 . Xenopus oocytes at 208C func-
tionally expressed both proteins which at 378C in
mammalian cells were retained in the endoplasmic
reticulum. Recombinant murine AE1 has also been
reported to be completely retained though in func-
.tional form in the endoplasmic reticulum of tran-
w xsiently transfected mammalian cells at 378C 20 ,
whereas a functionally significant fraction of AE1
accumulates at the surface of Xenopus oocytes
w x4,21–29 .
In addition to reliance on functionally informative
phenotypes in naturally occurring mutations, selec-
tion strategy for site-directed mutagenesis experi-
ments designed to investigate the structural bases of
AE1 transport function relies on algorithmic predic-
tions of secondary structure deduced from primary
structure and on results of chemical modification of
red cells with group-specific reagents. In the course
of routine plasmid subcloning in E. coli, we noticed
a loss-of-function phenotype which arose in mouse
AE1 cDNA. This paper presents the characterization
of that mutation in Xenopus oocytes. The loss-of-
function was secondary to a double mutation in
residues adjacent to a residue which is mutant in
human hereditary spherocytosis. These residues re-
side in a region of AE1 whose topography remains
uncertain.
In addition, the role of the mouse AE1 carboxy-
terminal cytoplasmic tail was examined in Xenopus
oocytes. The amino-terminal cytoplasmic domain of
erythroid AE1 serves as a binding site for cyto-
skeletal proteins, glycolytic enzymes, and denatured
w xhemoglobin 1,2 . Removal of most of this region
corresponding approximately to the membrane-prox-
imate tryptic cleavage site produces a polypeptide
which is still functional at the surface of the Xenopus
w xoocyte 28 . In contrast, a physiological role for the
much shorter, cytoplasmic carboxy-terminal cytoplas-
w xmic tail of AE1 30 had not been defined. We found
that removal of this carboxy-terminal tail in the form
of two distinct mutations resulted in loss of transport
function. In each of the two groups of mutations
( )M.N. Cherno˝a et al.rBiochimica et Biophysica Acta 1329 1997 111–123 113
studied, loss of transport function was accompanied
by loss of normal surface expression of the encoded
polypeptides. Thus, both groups of mutations dis-
rupted structures required for normal cell surface
accumulation of AE1 polypeptide, even in the ‘per-
missive’ Xenopus oocyte expression system.
Similar properties of a human AE1 mutant with a
shorter deletion of the C-terminal cytoplasmic
residues were reported after completion of this work
w x26 .
2. Materials and methods
2.1. Mutagenesis and assessment of mutant poly-
peptides
Mouse AE1 cytoplasmic domainrtransmembrane
domain chimeras were constructed via the EcoRV
 .site at nt 1339 Genbank accession no. X02677 .
Mouse AE1 point and deletion mutants were con-
structed by the dut -, ungy single-strand template
w xmethod of Kunkel et al. 31 with mutagenesis kits
 .from Amersham Arlington Heights, IL , Stratagene
 .  .La Jolla, CA , and BioRad Hercules, CA . The
mouse AE1 point mutation G2308T was constructed
using the mutagenic oligonucleotide 5X-GTTGCTG-
GTCTTTGGCATGGG-3X in the AE1 fragment SmaI
 .  .nt 2117 –SphI nt 2678 subcloned in M13mp19.
The AE1 point mutant G2316T was constructed in
the same M13mp19 subclone of AE1 using the muta-
genic oligonucleotide 5X-TCGTTGGCATTGGTGGG-
GTGG-3X. The mutant inserts were reconstructed as
cDNAs encoding full-length mutant AE1 poly-
peptides. The mutations were confirmed by DNA
sequencing.
The AE1 C-terminal deletion mutant D890 wasc
 .constructed in the AE1 fragment XbaI nt 1258 –
 .HindIII nt 3911 subcloned in M13 mp19 using the
mutagenic loop-out oligonucleotide 5X-GTGC-
CTCTCCGTCGTTGAGCGGCAGGCCCA-3X. In this
construct, AE1 residue Arg889 was followed by a
terminator codon. The AE1 C-terminal internal dele-
tion D890–917 was constructed in the same
M13mp19 subclone of AE1 using the loop-out oligo-
nucleotide 5X-GTGCCTCTCCGTCGTGGCCTG-
GATGAATAT-3X. In this construct, AE1 residue
Arg889 was followed by residue Gly918. Full-length
AE1 cDNAs containing each deletion mutation were
 . reconstructed with the SphI nt 2678 –HindIII nt
.3911 subfragments of each mutated insert. The in-
tegrity of the deletions was confirmed by DNA se-
quencing.
2.2. In ˝itro translation
Integrity of the mutant polypeptide products was
assessed by in vitro translation in rabbit reticulocyte
lysate, in the absence or presence of dog pancreatic
 .microsomes Promega, Madison, WI of polypeptides
w35 x labeled with S methionine NEN-Dupont, Boston,
.MA . Translation products were analyzed by SDS–
PAGE fluorography using the scintillant EnHance
 .NEN-DuPont . Procedures were as described previ-
w xously 23 .
2.3. Functional expression of heterologous AE poly-
peptides in Xenopus oocytes
cRNA was transcribed from linearized CsCl-puri-
fied plasmid DNA using kits from Stratagene and
 .from Ambion Austin, TX . Preparation of oocytes
and microinjection with cDNAs was performed as
w x 36 ypreviously described 23,27,29 . Cl influx experi-
ments were performed in ND-96, which contained in
.mM 96 NaCl, 2 KCl, 1.8 CaCl , 1 MgCl , and 52 2
N-2-hydroxyethylpiperazine-NX-2-ethanesulfonic acid
 .HEPES hemisodium salt. Chemicals were from
 .Sigma St. Louis, MO . Uptake periods were 60 min
in earlier experiments, and 15 min in later experi-
ments. In both cases, uptakes represented initial rates.
Statistical analysis of influx values for different
groups of oocytes was by ANOVA, followed by
t-tests for two samples with correction for multiple
comparisons by the Fisher LSD method. 36Cly efflux
experiments were also performed and analyzed as
w xpreviously described 24,27 as part of the determina-
tion of K for extracellular Cly.m
2.4. Antibodies
The affinity-purified antibody to mouse AE1 aa
w x214–228 was previously described 32 . The crude
antiserum to mouse AE1 aa 917–929 was prepared in
rabbits against peptide coupled through an added
N-terminal Cys to keyhole limpet hemocyanin via the
cross-linker maleimidobenzoyl-n-hydroxysuccinimide
 .ester Pierce, Rockford, IL .
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2.5. Detection of AE1 and mutant AE1 at the oocyte
surface
Metabolic labeling of cRNA-injected oocytes with
w35 x  . 35 S methionine NEN or with S-Trans-Label ICN,
.Costa Mesa, CA was performed as previously de-
w xscribed 23,29 . Forty-eight hours after cRNA injec-
tion, oocytes were incubated for 3 h in the absence or
 .presence of 5 mgrml chymotrypsin Sigma , fol-
lowed by washing, solubilization in Triton X-100,
w xand immunoprecipitation as previously described 23 .
The proportion of AE1 cleaved by exofacial proteoly-
sis was determined by scanning densitometry using
NIH Image v. 1.44. The use of surface proteolysis in
this assay assumes that the mutant and truncated
forms of AE1 studied retain sensitivity to exofacial
chymotryptic cleavage equivalent to that of wt AE1.
Moreover, the assay also assumes that the
antibody : antigen ratios optimized for wt AE1 also
apply to the mutant polypeptides studied below.
2.6. Construction of stable MDCK and 3T3 cell lines
stably expressing AE1 V728FrM730I
The BamHI fragment encoding the double-mutant
AE1 polypeptide was isolated from pWB3, and sub-
cloned into the amphotropic retroviral expression
vector, pDOL. pDOL-WB3 was purified and trans-
fected by the calcium phosphate precipitation tech-
nique into C-CRIP packaging cells. Replication-defi-
cient recombinant retrovirus released into the tissue
culture supernatant was used to infect MDCKII cells
and 3T3 cells. Infected cells were selected in humidi-
 .fied 5% CO in MEM Gibco, Bethesda, MD con-2
 .taining 10% calf serum. and G418 Gibco at 0.6
mgrml for MDCK cells and at 0.2 mgrml for 3T3
cells. Individual G4 18-resistant colonies were iso-
lated with plastic cloning rings, cloned, amplified in
the continued presence of G418, and screened for
mouse AE1 expression by northern blot and by im-
munoblot.
2.7. Pulse-chase experiments for determination of
AE1 half-life and endoH resistance
MDCK cell clones and 3T3 cell clones overex-
pressing human AE1 V728FrM730I were incubated
 .for 30 min in methionine-free DME medium Gibco ,
followed by 20 min in the same medium supple-
w35 x mented with 250 mCirml S methionine pulse pe-
.riod . Cells were then rinsed with methionine-free
DME, and normal MEM was restored for the indi-
cated chase times. Labeled cells were solubilized in
 .1% NP-40 lysis buffer containing in mM 140 NaCl,
.20 sodium phosphate, 2 PMSF, and 1 EGTA . Lysates
were cleared by centrifugation in a microfuge for 30
min at 18 000 rpm at 48C. Cleared lysates were
 .precleared with protein A-Sepharose Sigma , then
incubated for 2 h at 48C with affinity-purified anti-
mouse AE1 aa 917–929. After an additional 30-min
incubation with protein A-Sepharose, the antibody–
antigen–bead complexes were isolated, suspended in
SDS–PAGE load buffer, and subjected to SDS–
w xPAGE on 10% acrylamide gels 22,23 .
3. Results
3.1. Assignment of a spontaneous loss-of-function in
AE1 to mutations in its transmembrane domain
w xThe cDNA encoding mouse erythroid AE1 33
was subcloned from its original pUC13 carrier into
the transcription vector pSP64 to generate the recom-
binant plasmid, pWB3. cRNA transcribed from lin-
earized templates of this plasmid were injected into
Xenopus oocytes for assessment of functional expres-
sion. However, pWB3 cRNA did not confer on
oocytes the incremental transport of 36Cl-expected for
 . w xmouse erythroid AE1 eAE1 21 . In subsequent
w xexperiments 22 , cDNA cloning of mouse kidney
 .AE1 kAE1 revealed a translational initiation site at
Met80 of the eAE1 amino acid sequence. cRNA
transcribed from the kAE1 plasmid subclone pL2A
was expressed in Xenopus oocytes and conferred on
these oocytes increased 36Cl-uptake which was
blocked by addition of the transport antagonist, 4,4X-
X  .diisothiocyano-stilbene-2,2 -disulfonic acid DIDS .
In order to test the hypothesis that the functional
difference between erythroid AE1 cRNA transcribed
from pWB3 and kidney AE1 cRNA transcribed from
pL2A originated in a mutation in the pWB3 cDNA,
chimeric cDNAs were constructed, the corresponding
cRNAs were expressed in Xenopus oocytes, and the
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oocytes were subjected to assays of 36Cly influx. Fig.
1A shows the parental and chimeric constructs tested.
pBL contained the N-terminal cytoplasmic domain
from pWB3 and the C-terminal transmembrane do-
main from pL2A. The converse construct, pLB, con-
tained the N-terminal cytoplasmic domain from pL2A
and the C-terminal transmembrane domain from
pWB3. Fig. 1B shows that oocytes injected 48 h
earlier with cRNAs from plasmids pWB3 and pLB
did not differ in 36Cly uptake from oocytes injected
 .with water P)0.5 . In contrast, oocytes expressing
erythroid AE1 from the chimeric construct pBL P-
.0.00001 and oocytes expressing kidney AE1 from
 . 36 yplasmid pL2A Ps0.02 both displayed Cl up-
take exceeding that of water-injected oocytes 2.
This result suggested the presence of one or more
mutations in the AE1 transmembrane domain in plas-
mid pWB3. This hypothesis was confirmed by DNA
sequencing of pWB3 and pL2A between nt 1213
 .  .EcoRV and nt 3006 Bgl II of the murine AE1
sequence, encoding the region from aa 404 to beyond
the C-terminal aa 929 into the 3X-untranslated region.
This comparison revealed two missense mutations in
pWB3, G2308T and G2316T. The cDNA containing
these mutations encoded the double mutant AE1
polypeptide V728FrM730I. Residues 728 and 730 of
mouse AE1 are situated in putative transmembrane
 .span 9 TM9 in the postulated 14 transmembrane
span model of AE1, a still-debated model based on
hydropathy analysis, antibody reactivities, chemical
w xmodification, and proteolytic susceptibilities 26,34 .
However, the region between putative TM8 and TM11
is topographically the least well defined of the AE1
polypeptide. This region of the protein may span the
lipid bilayer one or three times, with transmembrane
spans of uncertain length.
2 In Fig. 1B, the 36Cy uptake activity displayed by oocytes
previously injected with cRNA transcribed from pL2A, though
significantly elevated compared to water-injected oocytes and
pWB3-expressing oocytes, is less than observed in oocytes of the
same experiment previously injected with cRNA transcribed from
pBL. This difference in expression level between pL2A-pro-
w xgrammed oocytes and oocytes programmed with pBL 27 or
w xwith anemic spleen mRNA 22 was not borne out in later
experiments.
Fig. 1. A: schematic of cRNAs expressed in Xenopus oocytes to
define region of AE1 in which spontaneous mutation led to loss
 .of function. pWB3 cross-hatched , mutant mouse erythroid AE1
 .plasmid; pL2A, mouse kidney AE1 plasmid shaded . pBL and
pLB are chimeras of complementary structure as indicated. B:
36Cly influx into oocytes injected with the cRNA products of the
indicated plasmids or with water. The chimera pBL expressed
Cly uptake, whereas the chimera pLB was inactive. Values are
means"S.E.M.
3.2. Determination of the roles of the indi˝idually
mutated amino acid residues 728 and 730
The individual AE1 mutations V728F and M730I
 .were constructed in a wt AE1 pBL background.
Fig. 2 shows in vitro translations which confirmed
that cRNA transcribed from each mutant plasmid
encoded a full-length AE1 polypeptide. As shown in
lanes 5, 7, and 9, AE1 V728F, AE1 M7301, and the
AE1 double mutant each encoded a polypeptide with
a mobility on SDS–PAGE close to or equal to that of
 .wt AE1 lane 1 , with a leading edge at ;105 kDa.
 .The double mutant V728FrM730I lane 9 accumu-
 .lated to the same degree as did wt AE1 lane 1 ,
though the single mutants accumulated to lower de-
grees. As previously observed with human AE1, in
w xvitro translation in the absence of microsomes 23,35
produced decreased yields of AE1 polypeptide
 .even-numbered lanes .
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Fig. 2. In vitro translation of AE1 polypeptides from cRNA templates encoding the indicated AE1 constructs, in the presence and absence
of pancreatic microsomes. Full-length translation products are the major bands in each lane containing microsomes ;105 kDa, or
.slightly lower in lanes 11 and 13 . Smaller bands likely represent products of premature chain termination andror proteolytic degradation.
Molecular mass markers are indicated at the left.
3.3. Biosynthetic accumulation and surface expres-
sion of mouse AE1 in Xenopus oocytes
Biochemical evidence for the heterologous expres-
sion of human erythroid AE1 at the surface of Xeno-
pus oocytes has been demonstrated by exofacial
w xcleavage with chymotrypsin 23,25,26 . However, al-
though functional expression of mouse AE1 in Xeno-
w xpus oocytes has been documented 21,22,27 , bio-
chemical evidence for oocyte surface expression of
the mouse AE1 polypeptide has not been presented
w x4 . For this reason, and in order to evaluate the
causes of the loss-of-function phenotype of mutant
AE1 encoded by pWB3, oocytes expressing mouse
erythroid AE1 were metabolically labeled, exposed to
chymotrypsin, and detergent-solubilized. Cleared
oocyte lysates were then subjected to immunoprecip-
itation with antipeptide antibodies to mouse AE1
residues 214–228 in the N-terminal cytoplasmic do-
w xmain 32 , and to mouse AE1 cytoplasmic C-terminal
residues 917–929 see Section 2: Materials and meth-
.ods .
Fig. 3 demonstrates that mouse AE1 is immuno-
precipitated by both antibodies to residues 917–929
 .  .lane 1 and to residues 214–228 lane 2 . However,
after exofacial chymotryptic digestion, antibody to
residues 214–228 also precipitates the non-glyco-
sylated N-terminal 60-kDa fragment generated by
cleavage in the exofacial loop between putative TM5
 .and TM6 lane 5 . In contrast, antibody to C-terminal
residues 917–929 fails to precipitate the 60-kDa frag-
ment, but recognizes the more diffuse, C-terminal
35-kDa chymotryptic fragment which is heteroge-
 .neously glycosylated lane 4 . Second rounds of im-
munoprecipitation with excess antibody failed to pre-
cipitate additional holo-AE1 or proteolytic fragments.
The fainter, more diffuse quality of the 35-kDa C-
terminal chymotryptic fragment autoradiographic
band led to the decision to follow the N-terminal
60-kDa chymotryptic fragment as the biochemical
index of AE1 expression at the oocyte surface in
subsequent experiments.
3.4. Functional expression of AE1 mutants V728F
and M730I and the double mutant
Fig. 4 shows that each single mutation, V728F and
M730I, allowed continued expression of AE1-media-
ted 36Cly uptake, but at only a fraction of the level of
wild-type AE1 function. In a total of 4 similar experi-
ments each involving 8–12 oocytes per group, V728F
and M730I expressed 28"14 and 41"12%, respec-
tively, of wt AE1 function measured as 36Cly up-
take. The individual mutations resulted in minimal
 .statistically insignificant changes in K for extra-m
y  .cellular Cl , 4.4"1.2 mM S.E.M., ns3 for wt
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Fig. 3. Expression of mouse AE1 at the surface of Xenopus
oocytes. Intact oocytes expressing wt AE1 and metabolically
w35 xlabeled with S methionine were incubated in the absence or
presence of chymotrypsin, then solubilized and subjected to
immunoprecipitation with the indicated anti-AE1 antipeptide anti-
bodies. AE1 holoprotein and the N-terminal CH60 fragment are
 .indicated by arrows right . The glycosylated C-terminal CH35
 .fragment is indicated by a bracket right . Molecular mass mark-
ers are indicated at the left.
 . AE1 vs. 8.8"2.9 mM ns2 for V728F Ps0.19
.  . vs. wt and 8.4"1.2 mM ns4 for M730I Ps
.0.07 vs. wt .
Coinjection into Xenopus oocytes of V728F with
M730I at a molar ratio of 1:1 exhibited neither
functional complementation nor inhibition, with 36Cly
uptakes comparable to those of either mutant alone.
Coinjection with wt AE1 cRNA of V728F at 1:1
cRNA ratio resulted in partial inhibition of wt AE1
 .transport activity Ps0.0002 , with greater inhibi-
tion when the V728Frwt AE1 cRNA ratio was 5:1
 .Ps0.01 compared to 1:1 coinjection . The double
mutant V728FrW730I was itself inactive in Xeno-
pus oocytes. When coexpressed with wt AE1 cRNA
at 1:1 cRNA ratio, the double mutant produced mini-
36 y mal inhibition of AE1-mediated Cl uptake P)
.0.2 . However, at a cRNA molar ratio of 5:1 the
double mutant inhibited wt AE1 function in these
 .assay conditions by ;35% Ps0.00001 . Interest-
ingly, the degree of inhibition produced by coexpres-
sion with wt AE1 of V728FrM730I was less than
that produced by coexpression of V728F at ratios of
 .  .1:1 Ps0.017 or 1:5 Ps0.037 . This may relate
to the lesser accumulation of doubly mutant polypep-
tide that could serve to decrease stability andror
efficiency of trafficking of wt AE1 polypeptide in the
oocyte.
To determine the degree to which reduced surface
expression of AE1 polypeptides could explain the
decreased functional activities of the above AE1 mu-
tant polypeptides, the levels of accumulation of the
AE1 polypeptides in the oocytes, and their suscepti-
bility to exofacial digestion with chymotrypsin were
 .examined. As shown in Fig. 5, both V728F lane 3
 .and M730I lane 5 accumulated to lower levels than
 .did wt AE1 lane 1 , whereas accumulation of the
double mutant polypeptide V728FrM730I was yet
 .more severely reduced lane 7 . The proportion of
total oocyte AE1 cleaved by exofacial digestion of
oocytes to yield the N-terminal chymotryptic frag-
ment P60 was reduced to 7% in oocytes expressing
Fig. 4. 36Cly influx into Xenopus oocytes mediated by wt AE1
 .ns23 , the spontaneous AE1 double mutant V728FrM730I
 .ns22 and AE1 polypeptides with each of the individual
 .mutations singly and coexpressed ns11 or 12 . Also shown are
effects on wt AE1 function of coexpression of V728FrM730I
and of V728F at mutant : wt molar ratios of 1:1 and 5:1 ns11–
.13 . The double mutation produced loss of function and the
single mutations reduced function. However, V728F appeared a
stronger inhibitor of wt AE1 function than V728FrM730I. Val-
ues are means"S.E.M.
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Fig. 5. Surface expression in Xenopus oocytes of the AE1 mutant
polypeptides V728F, M730I, and the double mutant. Procedures
were as in Fig. 3. Arrow at the left indicates the N-terminal AE1
chymotryptic fragment, CH60. Molecular mass markers are indi-
cated at the right.
either single mutant V728F or M730I lanes 4 and 6,
.respectively compared to 15% for wt AE1. P60
generated from the double mutant V728FrM730I
 .was below the threshold of detection lane 8 even
 .upon prolonged exposure not shown .
These results suggested that the decreased 36Cly
transport measured in oocytes expressing AE1 V728F
or M7301 could be largely attributed to decreased
quantity of mutant polypeptide at the oocyte surface
compared to wt AE1 polypeptide. The near absence
of 36Cly transport measured in oocytes expressing
the double mutant polypeptide V728FrM730I could
be attributed to severely decreased accumulation of
mutant polypeptide. The decreased accumulation of
mutant polypeptides could have been secondary to
decreased rates of biosynthesis or trafficking to the
surface, or to decreased stability at the surface or
prior to arrival at the surface. The near-normal accu-
mulation of the double mutant polypeptide in dog
 .pancreas microsomes in vitro Fig. 2 suggests that
the locus of altered trafficking or altered susceptibil-
ity to degradation is postendoplasmic reticulum.
3.5. AE1 V728FrM7301 exhibits rapid turno˝er in
mammalian cells
The discovery of the double point mutation in
pWB3 led to a new understanding of the kinetic
behavior of mouse AE1 stably transfected into MDCK
cells. Multiple clonal lines expressing AE1 were
produced using an expression vector in which the
AE1-coding portion was derived from pWB3. Thus,
the transfected AE1 turned out to contain the double
point mutation. As shown in Fig. 6A, the AE1
polypeptide in these cells exhibited a half-life of F2
h. Fig. 6B presents a possible explanation for this
short half-life. The heterologous AE1 V728FrM730I
was retained in the endoplasmic reticulum or the
cis-Golgi, since it remained completely susceptible to
digestion by endoglycosidase H even after 75 min of
chase. Consistent with this apparent sequestration
inside the cell, AE1 V728FrM730I in MDCK cells
was not susceptible to proteolysis by extracellular
 .chymotrypsin not shown . Comparable results were
obtained in multiple independent clones of mouse
3T3 cell stably transfected with mouse AE1 not
.shown and in transiently transfected HEK-293 cells
w x20 . If AE1 V728FrM7301 expressed in Xenopus
oocytes were similarly unable to leave the endoplas-
mic reticulum, becoming subject to accelerated prote-
Fig. 6. Instability of the protein product of pcDNA1-WB3 stably
transfected into MDCK cells. A: immunoprecipitation of heterol-
ogous mouse AE1 from whole cell lysates of stably transfected
w35 xMDCK cells after labeling with S methionine for 2 h, followed
by chase times of 0, 3, or 5 h. Similar results were observed in
three independent, clonal cell lines. B: endoglycosidase H suscep-
tibility of 35S-labeled heterologous mouse AE1 from MDCK cell
lysates after chase times of 0 or 75 min. Similar results were
obtained in experiments with five independent, clonal cell lines.
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Fig. 7. 36Cly influx into Xenopus oocytes mediated by the AE1
 .carboxy-terminal truncation mutants D 890 ns23 and D890–c
 .  . X917 ns22 compared with wt AE1 ns9 and with D3 -UTR
 .ns21 . Also shown are effects of mutant coexpression on wt
AE1 function at mutant : wt molar ratios of 1:1 and 5:1 ns9–
.10 . All mutant constructs shown in this figure lack the mouse
AE1 3X-UTR. Both truncations produced loss of function, but
only D890–917 substantially inhibited coexpressed wt AE1.
Values are means"S.E.M.
olytic degradation, its lack of accumulation would be
explained.
3.6. Functional consequences of remo˝al of the car-
boxy-terminal cytoplasmic tail of AE1
Though AE1 has two cytoplasmic domains, most
attention has focused on the larger N-terminal cyto-
plasmic domain, known to mediate important cyto-
skeletal binding functions. The function if any, of the
short C-terminal cytoplasmic domain had not been
addressed experimentally. In order to examine the
functional necessity of the presence of the C-terminal
cytoplasmic domain, C-terminal truncations of mouse
AE1 were constructed which also lacked the portion
X  .of the 3 -untranslated region nt 2791–3785 present
in the constructs presented above. Fig. 7 shows that
though deletion of only this portion of the 3X-untrans-
 X .lated region from the AE1 cRNA D3 -UTR pro-
duced no diminution in AE1-mediated 36Cly uptake,
removal of the C-terminal 39 amino acids following
R889 completely abolished transport function
 .D 890 . Attachment of the C-terminal residues 918–c
929 directly to R889 produced no further increase in
36 y  .Cl uptake D890–917 .
Fig. 7 also shows the results of coexpression of
these mutant AE1 polypeptides with wt AE1. D 890c
coexpression slightly inhibited wt AE1 function
 .whether at 1:1 P)0.0004 or 5:1 molar cRNA
 .ratios P)0.04 , but these degrees of inhibition did
 .not differ Ps0.47 . Coexpression of D890–917
with wt AE1 at a 1:1 molar cRNA ratio showed
 .greater inhibition of wt AE1 function P-0.0005 ,
and the degree of inhibition increased when mutant
cRNA exceeded wt cRNA by a 5:1 molar ratio
 y6 .P-10 compared to 1:1 .
Metabolic labeling and immunoprecipitation were
again used to evaluate the degree to which the loss-
of-function which accompanied deletion of C-termi-
nal residues of AE1 could be explained by defects in
polypeptide biosynthesis or in oocyte surface expres-
sion. Fig. 2 demonstrates that in the presence of
microsomes, D 890 accumulated to wt levels, butc
that D890–917 showed reduced accumulation lanes
.11–14 . Fig. 8 compares oocyte surface expression of
Fig. 8. Surface expression in Xenopus oocytes of the AE1 mutant
 .polypeptides D 890 and D890–917. Arrowhead left indicatesc
the N-terminal AE1 chymotryptic fragment, CH60. Molecular
mass markers are indicated at the right.
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wt AE1 with that of D 890 and of D890–917. Totalc
accumulation of both truncated AE1 polypeptides
was substantially reduced compared to wt AE1. Gen-
eration of CH60 by exofacial chymotryptic cleavage
of the truncated AE1 polypeptides was below the
threshold of autoradiographic detection. Thus, de-
creased accumulation and decreased surface delivery
of mutant AE1 polypeptides D 890 and of D890–917c
likely suffices to explain the absence of increased
36Cly uptake by oocytes which express them.
Inhibition of wt AE1 function by D890–917 was
not replicated by coexpression of N-terminal soluble
fragments of AE1. Coexpression of neither the entire
N-terminal cytoplasmic domain of AE1 D 405,c
.amino acid residues 1–405, ns3 frogs, 25 oocytes
nor of the shorter N-terminal fragment D 122 ns1c
.frog, 10 oocytes produced any inhibition of wt
mouse AE1 function. The polypeptides encoded by
both of these truncated AE1 cRNAs stably accumu-
lated in reticulocyte lysate translation reactions not
.shown . Curiously, however, when coexpressed with
wt human AE1, mouse AE1 D 405 did produce mildc
w xinhibition of wt transport function 23 .
4. Discussion
This paper presents a functional analysis of muta-
tions in two regions of the mouse AE1 anion ex-
changer polypeptide. The first region is in putative
transmembrane span 9, and was detected in the course
of examining a spontaneously arising AE1 cDNA
which exhibited a loss-of-function phenotype. The
second region is the carboxy-terminal cytoplasmic
tail of AE1. Mutations in both regions either reduced
or abolished AE1-mediated 36Cly influx in Xenopus
oocytes. Reduction or loss of function paralleled and
could be explained by reduction or loss of accumula-
tion of AE1 polypeptide in the oocyte plasma mem-
brane. The double mutant in putative transmembrane
span 9 was also impaired in trafficking and short-lived
in transfected MDCK cells and 3T3 cells.
4.1. Mutations in AE1 residues 728 and 730
T he loss-o f-function doub le m utan t,
V728FrM730I, arose in a region of AE1 with still
unknown topography and function. That region is
often described for convenience as transmembrane
span 9. The topographical dispositions of the putative
seventh and eighth transmembrane spans of AE1 are
determined by the presence in the exofacial loop
connecting them of N-linked glycan and of serologi-
w xcal blood group determinants 13,15 . Their predicted
topographical disposition is further supported by the
ability of transmembrane span 7 to express signal
w xsequence function 35 . The integrity of the cytoplas-
mic loop between putative transmembrane spans 8
and 9 has been shown necessary for delivery of
functional AE1 to the Xenopus oocyte surface in the
w xabsence of coexpressed glycophorin A 26 . How-
 .ever, human AE1 residue E681 mouse E699 is also
accessible to the extracellular aqueous space, and
constitutes part of the anion translocation pathway
w x24,36,37 . More distally from the site of the double
mutation, the region around human AE1 K743 mouse
.K761 has been defined as cytoplasmic by intra-
w xcellular trypsinization 38 . This site is not susceptible
to exofacial trypsinization in mouse AE1 and AE2
expressed in Xenopus oocytes Chernova and Alper,
.unpublished . The same tryptic site has also been
found in the corresponding region of porcine AE2
w x39 . It remains uncertain whether the putative trans-
membrane spans 9–12 portrayed in the model of
w xWood 34 and by others in fact comprise 4 or only 2
transmembrane spans.
Interestingly, there exists a human AE1 mutant
allele associated with hereditary spherocytic anemia,
w xBand 3 Prague VIII, which encodes L707P 9 , corre-
sponding to residue 725 in the mouse. Mouse L725 is
predicted to interact with V728 the site of one of the
.mutations in pWB3 on the same surface of putative
transmembrane helix 9 of AE1. The red cells in this
autosomal dominant, obligately heterozygous syn-
drome, contain decreased levels of AE1 polypeptide
 .the mutant polypeptide was likely absent , though
the mutant mRNA was detected in blood by reverse
transcriptase-PCR. Thus, like mouse AE1
V728FrM7301 expressed in Xenopus oocytes and in
mammalian cells, human AE1 L707P in erythroid
precursor cells may exhibit instability secondary to
altered protein folding or helix packing.
Each single mutation in isolation, V728F and
M730I, produced a ;60% decrease in transport
function in Xenopus oocytes. When coexpressed,
neither of the single mutants complemented the other.
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Though the double missense mutation could have
arisen by chance, there are several indications that the
host Escherichia coli strain harboring the recombi-
nant mutant plasmid might have had a growth advan-
tage over bacteria harboring either the recombinant
wt AE1 plasmid or the single point mutants. In
particular, constitutive overexpression in E. coli of
human erythroid AE1 N-terminal cytoplasmic do-
w xmain has proved toxic to E. coli 40 , whereas over-
expression of human kidney AE1 cytoplasmic do-
main, lacking the 65 N-terminal amino acid residues
of the erythroid isoform, was compatible with bacte-
w xrial survival 41 . Similarly, high-level expression in
Saccharomyces cere˝isiae of the full-length mouse
erythroid AE1 polypeptide was unsuccessful, though
removal of the N-terminal 183 amino acid residues
allowed overexpression of functional anion ex-
w xchanger polypeptide to high levels 42 .
AE1 cytoplasmic domain-mediated toxicity in E.
coli might result from inhibition of glycolysis via
w xsequestration of aldolase 42 or glyceraldehyde de-
 w x.hydrogenase GAPDH 43 . Mammalian GAPDH
has also been reported to exhibit microtubule
bundlingrunbundling activity, sarcolemmal t-tubule
protein kinase activity, single-stranded DNA binding
w xactivity 43 , and weak uracil DNA-glycosylase
 . w xUDG activity 44 , important to DNA repair.
The impaired accumulation of the AE1
V728FrM730I doubly mutant polypeptide and its
absence at the surface of the Xenopus oocytes and
mammalian cells might clarify the long-standing sug-
gestion that the plasma membrane protein sorting
machinery of non-erythroid mammalian cells, as op-
posed to that of Xenopus oocytes, could not deliver
w xwt AE1 to the plasma membrane 20,39 . Interest-
ingly, the same group of investigators reported with-
out further comment the successful plasmalemmal
expression of wt murine AE1 as part of a more
w xrecent study 45 . This discrepancy might well be
explained by their inadvertent use of AE1
V728FrM730I or another loss-of-function mutant for
the earlier studies, whereas a wt cDNA might have
been used for the latter study.
A similar discrepancy has been presented for AE1
w xexpression in S. cere˝isiae 42,46 . Thus, overexpres-
sion of a variant of murine AE1 led to accumulation
in internal compartments, without delivery of the
heterologous polypeptide to the plasma membrane
w x42 . In contrast, a later report of overexpression of
the human AE1 transmembrane domain albeit at
.lower expression level successfully achieved func-
tional expression of the heterologous polypeptide at
w xthe yeast plasma membrane 46 . Perhaps mouse AE1
V728FrM7301 or another loss-of-function mutant
was used in the earlier S. cere˝isiae study.
4.2. Mutations at the AE1 carboxy-terminus
The second class of mouse AE1 mutants examined
in the present study was a pair of truncations of the
carboxy-terminal cytoplasmic region. These truncated
mouse AE1 polypeptides were accumulated in reticu-
locyte lysates and integrated into microsomal mem-
branes. In oocytes, however, total polypeptide accu-
mulation was reduced, and no mutant polypeptide
was detectable at the oocyte surface by proteolytic
cleavage. The lack of accumulation at the oocyte
surface of mouse AE1 lacking residues 890–917 and
w x890–929 is consistent with the finding 26 that hu-
man AE1 lacking residues 882–911 presented a simi-
lar phenotype in Xenopus oocytes: absence of 36Cly
influx, somewhat diminished accumulation of
polypeptide, and absence of detectable surface ex-
pression of polypeptide, not subject to rescue by
coexpressed glycophorin A.
Interestingly, the human AE1 hereditary spherocy-
tosis-associated mutation, R870W, is adjacent to
R871. This latter arginine residue corresponds to
mouse R889 and terminates the human equivalent of
the mouse AE1 mutant D 890. Human AE1 R870Wc
seems to be an obligate heterozygous mutation in
which mutant mRNA is present in reticulocytes, but
mutant protein appears to be absent in mature red
w xcells 23 .
The apparently lower total accumulation of the
murine AE1 mutant polypeptides D 890 and D890–c
917 in Xenopus oocytes compared with human AE1
w xD 881 26 may relate to the topography of thec
C-terminal transmembrane span. Murine D 890 ter-c
minates with Arg–Arg, suggesting a tryptic site in wt
AE1 which might be located at the cytoplasmic sur-
face of the lipid bilayer. Human D 881 correspondsc
to murine D 898, and terminates in both species withc
the dipeptide Arg–Glu.
The addition of residues 918–929 to residue 889
of mouse AE1 in the mutant D 890 did not rescuec
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the loss-of-function phenotype in the present study.
Rather, the presence of residues 918–929 appeared to
increase the mutant’s inhibitory effect when coex-
 .pressed with wt AE1 Fig. 7 . Taken together with
the proteolytic susceptibility of the AE1 C-terminus
 .see below , these data are compatible with the C-
terminal amino acids serving as a site of intramolec-
ular or intermolecular interaction with another do-
main of AE1 or with an another polypeptide.
w xMori et al. 47 reported on the proteolytic suscep-
tibility of this carboxy-terminal region of AE1, build-
ing on their earlier characterization of tryptic peptides
of the AE1 transmembrane domain which became
protease-susceptible only following membrane treat-
ment with NaOH. Pretreatment of membranes with
10 mM NaOH, a concentration which preserved the
ability of AE1 to bind to the extracellular antagonist
H DIDS and undergo intramolecular crosslinking,2
allowed subsequent proteolytic release of 27% of the
human AE1 carboxy-terminal peptide Ala893–Val911
 911 929corresponding to mouse AE1 Val –Val . Pre-
treatment of membranes with 40–100 mM NaOH
allowed subsequent proteolytic release of up to 85%
of this carboxy-terminal peptide. Similar patterns were
observed for proteolytic release of five additional
peptides encoding putative hydrophilic loops connect-
w xing transmembrane segments 48 . In contrast, only
25% of the human AE1 tryptic peptide Asn880–Lys892
 .corresponding to mouse AE1 E898–K910 was re-
leased upon digestion of membranes previously
treated with 100 mM NaOH. Moreover, the candidate
901 902 tryptic site Arg –Asp which in the correspond-
ing sequence Leu919–Asp920 of mouse AE1 is not a
.tryptic site was resistant to digestion even following
w xmembrane pretreatment with 100 mM NaOH 47 .
The degree of alkali resistance of tryptic sites can
be considered an inverse index of the degree of
exposure of that site within the polypeptide in the
context of the membrane. In this light, the inability to
detect in alkali-treated membranes any peptide gener-
ated from tryptic cleavage at human AE1 Arg870–
Arg871 also suggests that this site is shielded. Since
seven hydrophobic residues follow human AE1 Arg871
 .and mouse R889 , the cytoplasmic terminus putative
879 TM14 is likely nearer to human AE1 Arg mouse
. 871  .R897 than to human Arg mouse R889 . Mori et
w xa l. 47 suggested tha t the sequence
 .  .VrL EXXXLD ArG DD, found in the carboxy-
terminal cytoplasmic regions both of AQP1 and of
human and mouse AE1, might contribute to a role of
the C-terminal cytoplasmic region in trafficking to
the cell surface. Removal of the carboxy-terminal
cytoplasmic tail of AQP1 containing the above se-
.quence also led to AQP1 retention within the Xeno-
pus oocyte.
It was of interest to assess the effects on wt AE1
function of coexpression of mutant AE1 poly-
peptides, since AE1 solubilized in non-ionic deter-
gent from the red cell membrane exists as dimers and
w xtetramers 6,26,40,49 , and the AE1 mutant Southeast
 .Asian Ovalocytosis D400–408 forms hetero-
w xoligomers with wt AE1 49 . The loss-of-function
mutants studied did inhibit wt AE1 function. As was
w xfound for human AE1 Prague I 23 , the mechanism
appeared to be via interference with accumulation of
normal protein levels at the oocyte surface. However,
the stoichiometry of inhibition was not compatible
with simple dominant negative effects exerted within
dimeric or tetrameric units.
In summary, mutations in two previously unexam-
ined regions of mouse AE1 led to loss-of-function
phenotypes in the Xenopus oocyte expression sys-
tem. Loss of function was secondary to decreased
accumulation of the mutant polypeptides at the oocyte
surface.
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